Omega-3 Concentrates Firm KD Pharma Targets U.S. Market

Omega-3 concentrates supplier KD Pharma (Bexbach, Germany) plans to increase market share in the U.S. dietary supplements market. The company has hired Brooklyn, NY-based ingredients distributor Nutribiolink to commercialize its patented, high-grade fish oils in the United States.

The company recently increased its production capacity to 2,000MT annually. Omega-3 concentrates are produced in a certified-GMP pharmaceutical facility.

KD Pharma’s patented kd-pür supercritical extraction process is said to enable a more-concentrated omega-3 fatty acid dose-up to 99% EPA and/or DHA-which it says exceeds concentrations possible using traditional methods. The kd-pür process employs dual technologies: supercritical CO2 fluid extraction and supercritical fluid chromatography. “This gives our customers the ability to decrease the delivery size for the same daily dosage, or to increase the dosage in the same soft-gel size, both lowering the manufacturing costs,” said Peter Lembke, KD Pharma’s vice president of sales and business development, in a press release.

Additionally, kd-pür gently extracts omega-3 fatty acids without applying excessive heat (<120° F). And the process works without chemical solvents or exposing oils to oxygen. “This does not only ensure the protection from oxidation of the product, but also from contamination from microorganisms that cannot survive in an oxygen-free atmosphere, as well as removing harmful substances such as contaminants, heavy metals, [and] PCBs,” Lembke said. kd-pür enables higher reproducibility and consistency from batch to batch, the company adds.

On the Nutribiolink partnership, Chris Hachey, KD Pharma’s director of sales and marketing, says, “We chose Nutribiolink to represent KD Pharma omega-3 oils in the U.S. not only because of their extensive industry contacts, but also because they have the technical knowledge that is required to promote high-grade fish oils.”